Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
55.87
+4.37 (8.49%)
Jul 10, 2026, 3:00 PM CST
SHA:688513 Revenue
Chengdu Easton Biopharmaceuticals had revenue of 326.26M CNY in the quarter ending March 31, 2026, with 6.75% growth. This brings the company's revenue in the last twelve months to 1.35B, up 0.87% year-over-year. In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B, down -1.36%.
Revenue (ttm)
1.35B
Revenue Growth
+0.87%
P/S Ratio
7.20
Revenue / Employee
913.52K
Employees
1,480
Market Cap
9.74B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.33B | -18.37M | -1.36% |
| Dec 31, 2024 | 1.35B | 232.63M | 20.82% |
| Dec 31, 2023 | 1.12B | -53.39M | -4.56% |
| Dec 31, 2022 | 1.17B | 147.58M | 14.43% |
| Dec 31, 2021 | 1.02B | 101.02M | 10.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.93B |
| Aurisco Pharmaceutical | 1.68B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Nanjing Vazyme Biotech | 1.41B |
| Liaoning Chengda Biotechnology | 1.31B |
| Hualan Biological Vaccine | 1.20B |
| Acrobiosystems | 887.21M |